This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knight, J. A. Articles by Ozcelik, H. Search for Related Content PubMed PubMed Citation Articles by Knight, J. A. Articles by Ozcelik, H.

Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry

¹ Division of Epidemiology and Biostatistics, and ³ Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital; ² Department of Public Health Sciences, University of Toronto; ⁴ Ontario Cancer Genetics Network, Cancer Care Ontario; and ⁵ Department of Laboratory Medicine and Pathobiology, and ⁶ Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada

There are several genes that code for enzymes, including various forms of superoxide dismutase and glutathione peroxidase, that protect the cell against oxidative damage that, in turn, can lead to carcinogenesis. There are a few common genetic polymorphisms in these genes that lead to altered proteins. Three that have been identified are SOD2 Val-9Ala, GPX1 Pro198Leu, and the GPX1 GCG repeat (three alleles with four, five, or six repeats). The SOD2 variant has been associated with increased breast cancer risk in two studies. The GPX1 variants have not been studied with respect to breast cancer, but Pro198Leu has been associated with lung cancer. We conducted a case-control study of these three polymorphisms in incident, invasive breast cancer in Caucasian women under 55. There were 399 cases and 372 controls genotyped, of whom 488 were premenopausal, 208 postmenopausal, and 75 of unknown menopausal status. We were unable to replicate the previously observed association with SOD2 Val-9Ala and also found no association between breast cancer and GPX1 Pro198Leu. However, the allele of GPX1 containing four GCG repeats was significantly associated with breast cancer risk in premenopausal women (odds ratio, 1.55; 95% confidence interval, 1.04–2.30 for carriers versus noncarriers). There is a significant trend of increasing risk with increasing number of alleles with four GCG repeats (P = 0.03). This variant has not previously been reported to be associated with breast cancer.

This article has been cited by other articles:

				The Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst, October 4, 2006; 98(19): 1382 - 1396. [Abstract] [Full Text] [PDF]

				G. Ravn-Haren, A. Olsen, A. Tjonneland, L. O. Dragsted, B. A. Nexo, H. Wallin, K. Overvad, O. Raaschou-Nielsen, and U. Vogel Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study Carcinogenesis, April 1, 2006; 27(4): 820 - 825. [Abstract] [Full Text] [PDF]

				J. Ahn, M. D. Gammon, R. M. Santella, M. M. Gaudet, J. A. Britton, S. L. Teitelbaum, M. B. Terry, A. I. Neugut, and C. B. Ambrosone No Association Between Glutathione Peroxidase Pro198Leu Polymorphism and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2459 - 2461. [Full Text] [PDF]

				R. L. Milne, J. A. Knight, E. M. John, G. S. Dite, R. Balbuena, A. Ziogas, I. L. Andrulis, D. W. West, F. P. Li, M. C. Southey, et al. Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 350 - 356. [Abstract] [Full Text] [PDF]

				V. Diwadkar-Navsariwala and A. M. Diamond The Link between Selenium and Chemoprevention: A Case for Selenoproteins J. Nutr., November 1, 2004; 134(11): 2899 - 2902. [Abstract] [Full Text] [PDF]